TG Therapeutics Inc
NASDAQ:TGTX
| Market Cap (Intraday) | 4.71B |
| Current PE | 77.96 |
| Forward PE | 38.59 |
| 2yr Forward PE | 17.05 |
| 10-Day MA | $28.77 |
| 50-Day MA | $33.39 |
| 200-Day MA | $34.39 |
TG Therapeutics Inc Stock, NASDAQ:TGTX
3020 Carrington Mill Boulevard, Suite 475, Morrisville, North Carolina 27560
United States of America
Phone: +1.212.554.4484
Number of Employees: 338
Description
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.